This is a medicine used to treat certain types of cancer, specifically multiple myeloma. It works by stopping the growth of cancer cells. It's often given with other drugs like bortezomib and dexamethasone.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Panobinostat, sold under the brand name Farydak, is an oral cancer medicine for multiple myeloma, a cancer of the plasma cells in the bone marrow. It is used only in combination with bortezomib (an injected myeloma drug) and dexamethasone (a steroid), for people whose myeloma has come back or stopped responding after at least two earlier treatments, including bortezomib and an immunomodulatory drug such as lenalidomide or thalidomide. The US Food and Drug Administration (FDA) granted Farydak accelerated approval in 2015, based on how long it kept myeloma from worsening. That kind of approval depends on a later trial confirming real clinical benefit. The confirmatory trial was never completed, and at the manufacturer's request the FDA withdrew Farydak's US approval in March 2022, so it is no longer available as a prescription product in the United States. It remains authorized in the European Union. People in the US are most likely to meet it in their past treatment records, in clinical trials or in care abroad, while many newer myeloma treatments have become available.
Inside every cell, DNA is wound around proteins called histones. Enzymes called histone deacetylases (HDACs) adjust how tightly that DNA is packed, which helps decide which genes are switched on. Panobinostat is an HDAC inhibitor: by blocking these enzymes, it loosens the packing and changes which genes the cell reads, along with the behavior of other proteins the enzymes act on. In laboratory studies, this pushed some cancer cells to stop dividing or to die, with a stronger effect on tumor cells than on normal cells. How these gene and protein changes add up to benefit in a person is not fully understood, and panobinostat has been studied and approved only as part of a combination with bortezomib and dexamethasone, not on its own.
Panobinostat comes as capsules taken by mouth. It follows a three-week cycle: a dose every other day, three times a week, for the first two weeks, then a week off. Bortezomib injections and dexamethasone tablets follow their own schedule within the same cycle, so the care team usually provides a written calendar. Treatment typically runs for 8 cycles and may continue for another 8 (about 48 weeks in total) if it is helping and side effects are manageable. The capsules are swallowed whole with a glass of water, at about the same time on each dosing day, with or without food. They should not be opened, crushed or chewed. A missed dose can be taken up to 12 hours late; after that, skip it. If vomiting follows a dose, do not take another; wait for the next scheduled one. Side effects often lead to a pause or a lower dose, so take only the dose currently prescribed. Before starting and throughout treatment, the team checks blood counts (usually weekly), liver tests, an electrocardiogram (ECG, a recording of the heart's electrical activity) and blood levels of potassium and magnesium.
Diarrhea is the side effect people most need to prepare for. About two-thirds of people in the main trial had it, and for a quarter it was severe, which is why it carries a boxed warning (the FDA's most prominent warning). It can begin at any point in treatment. People are asked to have an antidiarrheal medicine at home before the first dose and to contact the care team as soon as diarrhea starts, or with ongoing vomiting or signs of dehydration. Fatigue, nausea, poor appetite, fever and swelling in the legs are also common. Panobinostat strongly lowers blood counts, especially platelets, the cells that help blood clot. Low platelets can lead to serious bleeding, and low white cells raise the risk of infections such as pneumonia, which caused deaths in the trial. Contact the care team right away about any fever or sign of infection, and about bleeding, unusual bruising or blood in stool or urine. The second boxed warning covers the heart: reduced blood flow to the heart and dangerous rhythm changes have occurred, some fatal. Report a fast, slow or pounding heartbeat, lightheadedness, new shortness of breath or new leg swelling promptly. Chest pain or fainting needs emergency care: call 911. In the trial, about a third of people stopped panobinostat because of side effects, most often diarrhea, fatigue or pneumonia.
Several medicines and foods change how much panobinostat reaches the blood. Strong CYP3A inhibitors (drugs that slow the liver enzyme that breaks it down, such as the antifungals ketoconazole and voriconazole, the antibiotic clarithromycin and some HIV medicines) raise its level and call for a lower dose. Strong inducers, which speed that enzyme up, lower its level and should be avoided. Grapefruit, pomegranate and star fruit, including their juices, act like inhibitors and should be avoided during treatment. Because panobinostat can affect heart rhythm, it is generally not combined with heart rhythm medicines such as amiodarone or sotalol, or with other drugs that prolong the QT interval (a measure on the ECG of how long the heart takes to reset between beats), such as methadone. Some anti-nausea medicines carry the same risk and are used only with extra ECG checks. Panobinostat also slows the clearance of certain drugs, including metoprolol (a blood pressure medicine) and venlafaxine (an antidepressant). Check any new prescription, laxative or supplement with the care team first. It is not started in people with a recent heart attack, unstable angina (chest pain from poor blood flow that is new or worsening), significant ECG abnormalities or an active infection. It can harm a developing baby: people who could become pregnant should use effective contraception during treatment and for at least 3 months afterward, and men should use condoms during treatment and for 6 months afterward. Breastfeeding is not recommended during treatment.
Treatment is intensive, especially in the early cycles. Expect frequent clinic visits for bortezomib injections and blood tests, regular ECGs, and possible platelet transfusions or medicines to support white cell counts. Doses are often paused or reduced to manage diarrhea, low counts or other effects, and this is a normal part of using the drug rather than a sign that treatment has failed. The benefit is measured in time before the myeloma worsens. In people who had already received bortezomib and an immunomodulatory drug, adding panobinostat extended that time from a median of about 6 months to about 10.6 months, although the trial did not show that people lived longer overall. The team uses regular tests to judge whether the myeloma is responding, and treatment usually ends after a set number of cycles, if the myeloma progresses or if side effects outweigh the benefit.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Panobinostat, what you've noticed, or ask the community a question.